Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Chronic typical antipsychotic use causes motor side effects like tardive dyskinesia (TD).
• TD is characterized by involuntary movements and may involve D2 receptor hypersensitivity, inflammation, and oxidative stress.
• Current TD treatments have limited efficacy and significant side effects.

Purpose of the Study:

• To investigate the potential antidyskinetic effects of cannabigerol (CBG) in a mouse model of tardive dyskinesia.
• To evaluate if CBG can prevent, ameliorate, or reverse haloperidol-induced vacuous chewing movements.
• To assess CBG's impact on motor activity and specific neurobiological markers.

Main Methods:

• Mice received haloperidol to induce vacuous chewing movements.
• Mice were treated with cannabigerol (CBG) at doses of 3 and 10 mg/kg.
• Evaluated effects on vacuous chewing, motor activity, FosB expression, and microglia morphology.

Main Results:

• Cannabigerol (CBG) significantly reduced haloperidol-induced vacuous chewing movements.
• CBG did not impair normal motor activity or exacerbate haloperidol-induced hypokinesia.
• No significant reversal of existing motor effects was observed; FosB expression and microglia morphology remained unchanged.

Conclusions:

• Cannabigerol (CBG) demonstrates preventive and ameliorative effects against antipsychotic-induced dyskinetic movements.
• Further research is warranted to explore CBG's therapeutic potential for tardive dyskinesia.
• CBG's mechanism of action in TD requires further investigation, as it did not impact FosB or microglia markers in this study.